AI Summary

A longitudinal study published in eClinicalMedicine examined the international approval of medicines developed in China from 1990 to 2025. The research tracked how many of those drugs received regulatory clearance in the United States, with additional comparisons to European and other global markets. The analysis used the U.S. as the primary reference point to assess the pace and extent of Chinese drug approvals abroad. The study highlights a growing presence of Chinese‑developed medicines in major international regulatory jurisdictions over the past three decades.

AI summaries can be wrong sometimes—always verify important details using the source article.